Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jun 10, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Completed study drug treatment in the parent study VX22-445-122 Part B (NCT05882357) OR had study drug interruption(s) in the parent study but did not permanently discontinue study drug and completed study visits up to the last scheduled visit of the Treatment Period of the parent study
- Key Exclusion Criteria:
- • History of drug intolerance in the parent study that would pose an additional risk to the participant
- • Current participation in an investigational drug trial other than the parent study
- • Other protocol defined Inclusion/Exclusion criteria may apply.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southampton, , United Kingdom
Leeds, , United Kingdom
London, , United Kingdom
Rotterdam, , Netherlands
Hannover, , Germany
Vancouver, , Canada
London, , United Kingdom
Liverpool, , United Kingdom
Toronto, , Canada
Bern, , Switzerland
Berlin, , Germany
South Brisbane, , Australia
Copenhagen, , Denmark
Parkville, , Australia
Essen, , Germany
Cardiff, , United Kingdom
Nedlands, , Australia
Zurich, , Switzerland
Berlin, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported